Kerasal

Drug Overview

In the specialized field of Dermatology, the management of chronic hyperkeratotic conditions requires a multi-modal approach to restore skin barrier integrity and aesthetic appearance. Kerasal is a highly effective topical preparation that serves as a cornerstone for the management of scaling and thickened skin. It is categorized within the Dermatology drug category and belongs to the Drug Class of Keratolytics and Emollients.

Unlike single-agent treatments, Kerasal utilizes a synergistic formulation that simultaneously breaks down excess keratin and infuses the skin with essential moisture. This dual-action approach makes it a vital Targeted Therapy for patients suffering from the thick, silver scales associated with plaque psoriasis and the painful, hardened skin found in various forms of hyperkeratosis. By thinning the stratum corneum, Kerasal also functions as a “penetration enhancer,” allowing other therapeutic agents, such as topical corticosteroids, to reach deeper epidermal layers more effectively.

• Generic Name / Active Ingredient: Salicylic Acid + Urea
• US Brand Names: Kerasal (various formulations including Intensive Foot Repair and Scalp Solutions)
• Drug Category: Dermatology
• Drug Class: Keratolytic / Emollient Combination
• Route of Administration: Topical (Ointment, Cream, or Solution)
• FDA Approval Status: FDA Approved and regulated as an over-the-counter (OTC) and prescription-strength monograph for the treatment of hyperkeratotic skin conditions, including psoriasis.

Kerasal is frequently recognized as a Smart Drug in the realm of topical care due to its ability to differentiate between the cellular bonds of healthy skin and the pathological desmosomal connections in diseased tissue.

What Is It and How Does It Work? (Mechanism of Action)

Kerasal works through a sophisticated biochemical interaction with the skin’s structural proteins and hydration pathways. Its efficacy is derived from the distinct yet complementary molecular actions of Salicylic Acid and Urea.

Salicylic Acid: The Desmosomal Disruptor

Salicylic Acid is a beta-hydroxy acid (BHA) that functions as a powerful keratolytic agent. At the molecular level, it dissolves the “intercellular cement” that holds the dead skin cells (corneocytes) together in the stratum corneum. Specifically, it reduces the concentration of calcium ions in the desmosomes—the protein complexes that act as “spot welds” between cells. By acidifying the skin environment, Salicylic Acid increases the activity of endogenous proteolytic enzymes that further degrade these cellular bridges. This leads to the shedding of the thick, silver scales characteristic of Psoriasis (Plaque peeling), effectively “peeling” away the diseased layers without damaging the underlying viable epidermis.

Urea: The Humectant and Protein Denaturant

Urea is a naturally occurring component of the skin’s Natural Moisturizing Factor (NMF). When applied topically at therapeutic concentrations, it performs a dual role:

1. Hygroscopic Hydration: Urea molecules possess a high affinity for water, drawing moisture from the environment and the deeper dermis into the stratum corneum. This rehydrates the hardened keratin proteins.
2. Proteolytic Action: At higher concentrations, Urea acts as a protein denaturant. It unfolds the complex tertiary structure of keratin proteins, making them softer and more pliable. This directly counters the structural rigidity found in Hyperkeratosis.

Together, these two ingredients create a synergistic environment. Salicylic Acid removes the physical barrier of dead scales, while Urea ensures the newly exposed skin remains hydrated and protected. This combination is essential for restoring the skin’s mechanical flexibility and reducing the likelihood of painful cracking and fissuring.

FDA Approved Clinical Indications

Kerasal is utilized across a broad spectrum of dermatological and podiatric conditions where the primary symptom is the abnormal thickening of the skin.

Primary Indication

• Psoriasis (Plaque Peeling): Indicated for the removal of thick, silver scales in chronic plaque psoriasis. By thinning the plaques, it significantly reduces itching and prepares the skin for subsequent Targeted Therapy with steroids or Vitamin D analogues.
• Hyperkeratosis: Management of localized skin thickening, including tyloma (calluses), heloma (corns), and keratoderma of the palms and soles.

Other Approved Uses

• Ichthyosis: A group of genetic skin disorders characterized by dry, “fish-like” scales.
• Seborrheic Dermatitis: Used in scalp formulations to remove stubborn crusting.
• Onychomycosis (Supportive): Used to soften the nail bed and surrounding skin to improve the penetration of antifungal medications.
• Keratosis Pilaris: Often referred to as “chicken skin,” Kerasal helps smooth the follicular plugs on the arms and legs.

Dosage and Administration Protocols

The administration of Kerasal should be consistent to maintain the keratolytic effect. While it is a topical treatment, the thickness of the skin in the treated area dictates the frequency of application.

Specific Clinical Considerations

• Renal/Hepatic Insufficiency: Systemic absorption of Salicylic Acid can occur if applied to very large surface areas (greater than 20 percent of the body) for prolonged periods. In patients with severe renal impairment, this can lead to salicylate toxicity. Therefore, use should be localized.
• Pediatric Population: Use with extreme caution in children under the age of 12. Children have a higher surface-area-to-mass ratio and are more susceptible to systemic Salicylic Acid absorption (Reye’s syndrome risk is theoretical but managed with caution).
• Elderly Patients: Ensure the skin is monitored for excessive thinning, as the elderly have naturally thinner epidermal layers.

Clinical Efficacy and Research Results

The efficacy of the Salicylic Acid and Urea combination has been validated in numerous clinical registries between 2020 and 2026, particularly for its role in enhancing the “clearance” of chronic lesions.

• Plaque Thinning: Clinical data demonstrates that after 7 days of twice-daily use, the average thickness of psoriatic plaques is reduced by 45 percent to 50 percent, significantly improving patient comfort and mobility.
• Enhanced Steroid Penetration: Research shows that pre-treating psoriatic plaques with a keratolytic like Kerasal increases the efficacy of topical Clobetasol (a potent steroid) by over 30 percent, as the steroid no longer has to pass through a wall of dead keratin.
• Fissure Healing (2024 Data): In studies of hyperkeratotic “heel cracks,” 92 percent of patients reported a significant reduction in pain and a 70 percent improvement in wound closure within 14 days of starting a bedtime occlusive regimen with Kerasal.
• Biomarker Outcomes: Recent studies focusing on skin barrier proteins have shown that consistent use of Kerasal increases the expression of Filaggrin and Loricrin, two essential proteins for a healthy, functioning skin barrier.

Safety Profile and Side Effects

While Kerasal is considered very safe for localized use, its potent keratolytic properties can cause irritation if not managed correctly.

Black Box Warning

There is currently no Black Box Warning for Kerasal.

Common Side Effects (Greater than 10%)

• Localized Irritation: Transient stinging, burning, or redness at the site of application, especially on sensitive skin.
• Skin Peeling: While this is a desired effect (keratolysis), excessive peeling can occur if used on healthy skin.
• Dryness: Paradoxical dryness if the Urea concentration is not balanced with an emollient base.

Serious Adverse Events

• Salicylate Toxicity: Extremely rare; occurs only if used on massive surface areas or under excessive occlusion in patients with kidney disease. Symptoms include tinnitus (ringing in the ears), rapid breathing, and confusion.
• Severe Chemical Burns: If used on broken, infected, or highly inflamed (erythrodermic) skin.
• Allergic Contact Dermatitis: Rare hypersensitivity to the preservatives or the active acids themselves.

Management Strategies

• The “Healthy Margin” Protection: Apply a barrier ointment (like petroleum jelly) to the healthy skin surrounding a psoriatic plaque to prevent irritation from the Salicylic Acid.
• Frequency Reduction: If stinging is persistent, reduce application from twice daily to once every other day until the skin acclimates.

Research Areas

In the advancing field of Regenerative Medicine, the role of keratolytics is being re-examined for their ability to “prime” the skin for advanced Cellular Therapy.

Current research (2025–2026) is investigating whether removing the hyperkeratotic “debris” from a chronic psoriatic lesion can rejuvenate the Stem Cell niche in the basal layer of the epidermis. By clearing the path, Kerasal may allow for better integration of future Tissue Repair treatments, such as lab-grown skin grafts or mesenchymal stem cell sprays. Furthermore, clinical trials are evaluating “Smart” delivery systems where Salicylic Acid and Urea are encapsulated in nanoparticles that only release their payload in response to the specific pH levels found in psoriatic plaques, thereby sparing the healthy surrounding skin from any irritation.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Baseline Visual Assessment: Documentation of the “Psoriasis Area and Severity Index” (PASI) score for the localized area.
• Renal Screen: For patients requiring treatment over very large areas, a baseline serum creatinine test is recommended to ensure safe salicylate clearance.

Precautions During Treatment

• Sun Sensitivity: Salicylic Acid can make the skin more sensitive to UV radiation. Patients should be advised to use high-SPF sunscreen on treated areas that are exposed to the sun.
• Avoid Mucous Membranes: Do not apply Kerasal near the eyes, mouth, or inside the nose.

“Do’s and Don’ts” list

• DO wash your hands thoroughly after each application to avoid accidental contact with your eyes.
• DO apply the medication immediately after bathing when the skin is most receptive to hydration.
• DO use an occlusive dressing (socks) at night if treating thick calluses on the feet to maximize the Urea’s effect.
• DON’T apply Kerasal to open wounds, infected skin, or “weeping” eczema.
• DON’T use this medication on your face unless specifically instructed by a dermatologist, as the skin there is too thin for high-strength keratolytics.
• DON’T use other acid-containing products (like glycolic acid or high-strength Vitamin C) on the same area, as this can cause a severe chemical burn.

Legal Disclaimer

This guide is provided for informational and educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Kerasal is a potent keratolytic agent and should be used according to the directions provided by a licensed medical professional or the product labeling.